Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada

INTRODUCTION: We estimate the lifetime cost of treatment for moderate/severe symptoms associated with benign prostatic hyperplasia (BPH) in a cohort of Canadian men aged 50 to 59, and we evaluate the costs of 2 daily bioequivalent treatment options: fixed-dose combination (FDC) of dutasteride (0.5 m...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sayani, Amyn, Ismaila, Afisi, Walker, Anna, Posnett, John, Laroche, Bruno, Nickel, J. Curtis, Su, Zhen
Médium: Artigo
Jazyk:Inglês
Vydáno: Canadian Medical Association 2014
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896551/
https://ncbi.nlm.nih.gov/pubmed/24454593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.755
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky